<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02355873</url>
  </required_header>
  <id_info>
    <org_study_id>2013QX-FZC-001</org_study_id>
    <nct_id>NCT02355873</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Heparin-coated Surface-treated Polyacrylonitrile Membrane Hemofilter in Critical Ill CRRT Patients</brief_title>
  <official_title>Efficacy and Safety of Heparin-coated Surface-treated Polyacrylonitrile Membrane Hemofilter in Critical Ill CRRT Patients Continuous Renal Replacement Therapy Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      CRRT patients are generally critical ill patients with unstable conditions, such as low blood
      pressure,severe SIRS,et al. Acute kidney injury(AKI)is especially prevalent,with even two or
      more organ failure. CRRT serves as an important supportive therapy.Continuous anticoagulation
      is needed to prevent treatment interruptions due to clotting of the extracorporeal circuit.
      Unfractionated heparin or low molecular weight heparin both increase the risk of bleeding and
      heparin induced thrombocytopenia in such cases.However, the problem of CRRT without
      anticoagulation is the early filter clotting. An alternative method is the use of heparin
      coated hemofilter. The AN69 ST hemofilter, a surface-treated polyacrylonitrile membrane
      hemofilter, allows irreversible fixing of heparin to filter membrane, is able to reduce
      thrombogenic properties of the membrane. In this study, we observe the efficacy and safety of
      heparin-coated AN69 ST hemofilter in CRRT patients, and compare to the original AN69 membrane
      hemofilter.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2015</start_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The filter survival time of AN69ST and AN69 membrane hemofilter in each CRRT process</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of patients with early filter clotting in the scheduled CRRT using AN69ST and AN69 membrane hemofilter</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The number of patients in AN69ST and AN69 hemofilter group according to the final filter clotting grading</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of participants with the adverse events.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Critical Ill Patients</condition>
  <condition>Patients Needing Continuous Renal Replacement Therapy</condition>
  <arm_group>
    <arm_group_label>AN69ST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AN69ST:Surface-treated Polyacrylonitrile Membrane Hemofilter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AN69</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AN69:original Polyacrylonitrile Membrane Hemofilter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AN69ST hemofilter</intervention_name>
    <arm_group_label>AN69ST</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AN69 hemofilter</intervention_name>
    <arm_group_label>AN69</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Critical ill patients who need continuous renal replacement therapy

          -  Continuous anticoagulation therapy is not necessarily during CRRT process

        Exclusion Criteria:

          -  Patients needing continuous anticoagulation during each CRRT process

          -  Expectant survival time less than 72 hours

          -  Extremely unstable vital signs such as low blood pressure

          -  Any reasons that resulting in blood flow rate less than 150ml/min

          -  Pregnant women

          -  Patients allergic to heparin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tao Su, MD</last_name>
    <phone>861083575755</phone>
    <email>tao.su@bjmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Renal division,department of Medcine,Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Su, MD</last_name>
      <phone>+861083575755</phone>
      <email>tao.su@bjmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Qizhuang Jin, MD</last_name>
      <phone>+861083575687</phone>
      <email>jinqizhuang@medmail.com.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Tao Su, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qizhuang Jin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2015</study_first_submitted>
  <study_first_submitted_qc>January 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2015</study_first_posted>
  <last_update_submitted>February 6, 2015</last_update_submitted>
  <last_update_submitted_qc>February 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Tao Su</investigator_full_name>
    <investigator_title>Effect of heparin coated Surface-treated Polyacrylonitrile Membrane Hemofilter in Critical Ill CRRT Patients</investigator_title>
  </responsible_party>
  <keyword>heparin-coated</keyword>
  <keyword>surface-treated polyacrylonitrile membrane hemofilter</keyword>
  <keyword>critical ill</keyword>
  <keyword>acute kidney injury</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>continuous renal replacement therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

